Edgewise Therapeutics
IPO
A Movement in Muscle
- Headquarters
- Boulder, Colorado
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- edgewisetx.com
- Total Funding
- $585.0M
- Last Round
- $200.0M Growth EquityApr 2025
About
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral small-molecule therapies for serious skeletal and cardiac muscle diseases including Duchenne muscular dystrophy, Becker muscular dystrophy, and hypertrophic cardiomyopathy. Founded in 2017 and headquartered in Boulder, Colorado, the company uses its proprietary muscle biology platform to identify and advance muscle-selective drug candidates with the goal of improving function and quality of life for patients with rare muscle disorders.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account